Related Experiment Video
Updated: Jan 6, 2026

Skin Biopsy for Diagnosing Discoid Lupus Erythematosus
Published on: June 10, 2025
Pattern-Specific Loss of Desmoplakin I and II Immunoreactivity in Erythema Multiforme and its Variants: A Possible
Vernon J Forrester1, Benjamin Tran2, Stephanie C Hein3
1Department of Dermatology, University of Virginia, Charlottesville, VA.
Abstract:
Erythema multiforme (EM), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) comprise a family of mucocutaneous diseases associated with significant morbidity and mortality. Previous studies have confirmed the presence of autoantibodies to desmoplakin (Dp) I and II in patients with EM, SJS, and TEN. Truncated Dp production leads to characteristic changes visible on light microscopy: perinuclear clumping of keratin filaments and dyskeratotic keratinocyte. Based on these observations, the question arises as to whether a loss of Dp immunoreactivity in skin biopsies could serve as a diagnostic marker of EM, SJS, and TEN. This study analyzed Dp immunostaining patterns in 20 patients with EM or SJS/TEN. To assess the specificity of this approach, Dp immunostaining was also performed on specimens from patients with 5 potential histologic mimics of EM, SJS, and TEN. All of the samples from patients with EM, SJS, and TEN demonstrated absent or markedly diminished staining for Dp. A χ test demonstrated a statistically significant difference between the staining patterns in EM, SJS, and TEN and each of the other diagnostic groups that were investigated. This is the first report demonstrating statistically significant specificity of Dp staining patterns in EM/SJS/TEN as compared with other interface dermatitides.
Insights
Loss of desmoplakin (Dp) immunoreactivity in skin biopsies can help diagnose Erythema multiforme (EM), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN). This finding offers a specific diagnostic marker for these severe mucocutaneous diseases.
Area of Science:
- Dermatology
- Immunopathology
- Histopathology
Background:
- Erythema multiforme (EM), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) are severe mucocutaneous diseases with high morbidity and mortality.
- Autoantibodies to desmoplakin (Dp) I and II are implicated in EM, SJS, and TEN, leading to truncated Dp production and characteristic cellular changes.
- These cellular changes include perinuclear clumping of keratin filaments and dyskeratotic keratinocytes observed under light microscopy.
Purpose of the Study:
- To investigate whether absent or diminished desmoplakin (Dp) immunoreactivity in skin biopsies can serve as a diagnostic marker for EM, SJS, and TEN.
- To determine the specificity of Dp immunostaining patterns in differentiating EM, SJS, and TEN from other interface dermatitides.
Main Methods:
- Analyzed desmoplakin (Dp) immunostaining patterns in skin biopsy specimens from 20 patients diagnosed with EM or SJS/TEN.
- Performed Dp immunostaining on specimens from patients with five other conditions that histologically mimic EM, SJS, and TEN.
- Utilized a chi-squared (χ) test to statistically compare Dp staining patterns between the disease groups.
Main Results:
- All skin biopsy samples from patients with EM, SJS, and TEN showed absent or markedly diminished desmoplakin (Dp) staining.
- Dp immunostaining patterns were significantly different in EM, SJS, and TEN compared to the five investigated histologic mimics.
- This study provides the first statistically significant evidence for the specificity of Dp staining patterns in diagnosing EM/SJS/TEN.
Conclusions:
- Absent or diminished desmoplakin (Dp) immunoreactivity is a highly specific finding in skin biopsies of patients with EM, SJS, and TEN.
- Dp immunostaining represents a valuable and specific diagnostic marker for differentiating EM, SJS, and TEN from other interface dermatitides.
- This histopathological marker can aid in the accurate diagnosis of these severe mucocutaneous diseases.
Related Concept Videos
Desmosomes
Myocarditis II: Clinical Features and Diagnostic Tests

